


WuXi XDC and AbTis announce strategic partnership to advance nextgeneration ADCs

11 March 2025 | News

To drive and support the development of groundbreaking ADC therapeutics



WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), has announced the signing of a Memorandum of Understanding (MoU) with AbTis, a leading ADC biotechnology startup based in South Korea.

This partnership brings together AbTis' proprietary site-selective conjugation platform AbClick and China-based WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. The collaboration aims to accelerate ADC therapeutic innovation by integrating AbTis' cutting-edge technology into WuXi XDC's toolbox, while fostering new opportunities for global clients.

WuXi XDC will incorporate AbTis' advanced site-selective conjugation technologies including the AbClick Platform, which utilises affinity peptide-assisted linkers to enable precise and efficient antibody-drug conjugation. Additionally, WuXi XDC will facilitate potential collaborations between AbTis and its extensive client network, expanding the global reach of AbTis Technologies while unlocking synergistic market opportunities.

This collaboration highlights a shared commitment to advancing innovation and delivering state-of-the-art solutions to the bioconjugate drug industry. By enhancing CMC platform capabilities, both companies aim to empower clients to accelerate preclinical candidate selection, develop next-generation ADCs, and expedite CMC development timelines.